CCT241736 是一种口服生物可利用的双重 FLT3/AuRORa 激酶抑制剂，还抑制临床相关的 FLT3 耐药突变体，包括 FLT3-ITD 和 FLT3。它是 CCT137690 的高级类似物，是治疗人类恶性肿瘤的临床前开发候选物。

CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3, CCT241736, an advanced analog of CCT137690, is a preclinical development candidate for the treatment of human malignancies, and in particular AML in adults and children.

UNC2025 was capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examining phospho-Mer in leukemic blasts from mouse bone marrow.

1402709-93-6

C22H23Cl2N7

456.38

DMSO:75 mg/mL (164.34 mM),Need ultrasonic
H2O:< 0.1 mg/mL (insoluble)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years